Bayer has signed a deal to buy the radioisotope actinium-225 (Ac-225) at predetermined prices from BWXT Medical, a subsidiary of BWX Technologies.
The two companies expect supply to commence later this year. This announcement builds upon an agreement reached by the two companies in September 2021.
Ac-225 is used in targeted alpha therapies (TATs). This emerging field combines Ac-225 with specific tumor-seeking targeting moieties that deliver alpha radiation directly to tumors.
